Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVSRIPO and Atezolizumab in Recurrent Malignant Glioma
NCT03973879Phase 2Withdrawn
- Sponsor
- Istari Oncology
- Start
- Feb 2020
- Primary completion
- Jan 2024
01
Overview
A Phase 2 trial of lerapolturev in malignant glioma, sponsored by Istari Oncology. Planned start Feb 2020; status: withdrawn.
02
Drugs
lerapolturev
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT03973879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03973879.